NDAORALSOLUTION
Approved
Jun 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Paradione (paramethadione) is an oral solution small-molecule anticonvulsant approved in 1949 for seizure management. It is an oxazolidinedione derivative used primarily in refractory epilepsy and absence seizures. The drug's mechanism involves modulation of neuronal excitability, though detailed pharmacological classification is not extensively documented in modern literature.
LOE Approaching
As a legacy product nearing loss of exclusivity with minimal linked job activity, commercial teams are likely in maintenance mode with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Paradione offers minimal career advancement opportunity; roles are maintenance-focused and typically entry-level or lateral moves. Working on this product signals career plateau rather than trajectory growth, with limited visibility into modern drug development.
Regulatory Affairs SpecialistProduct Manager (Legacy/Portfolio)
Worked on PARADIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.